Monthly Archives: March 2014

Encouraging Biotech Innovation
March 31, 2014

Let’s face it, biotech entrepreneurs are innovation junkies.  We desperately want to deploy the most novel technologies to solve difficult problems in medicine and deliver new, life changing medicines for patients who need our help.  Independent of additional factors that

Leave a comment

Transformational Late Stage Drugs Delivered Through Deal-Making
March 21, 2014

Today’s biopharma industry has a richer and more exciting late stage pipeline of compelling new therapeutics than its had in years, drawing lots of enthusiasm from analysts and investors.  Goldman Sachs (GS) recently published a report on the “10 drugs


Chemistry’s Age of Enlightenment
March 20, 2014

Despite many decades of success, small molecule drug discovery appears to be increasingly challenged.  The likelihood of approval of a small molecule at phase 1 is approximately half that of a biologic; pharma companies have shifted their pipelines dramatically towards

1 Comment

The Rookie Year and the Biotech CEO
March 12, 2014

Five years ago I stepped into my first (and so far only) CEO role. It seems impossible that it was five years ago but I definitely still remember many moments from my rookie year as a CEO – both successes


Unlocking The Promise Of Biotech Startups: Learnings From Mars, Goliath, and Evolution
March 5, 2014

As an early stage biotech investor, the future of the industry and its structure are clearly important things to think about – especially since most of the drug programs our new startups are working on won’t get launched, if they


The Awesome Power Of Risk
March 3, 2014

Humans are supremely lousy at evaluating risk. We get nervous when we fly but not when we drive. We worry about terrorist attacks when we’re far more likely to die in our own bathrooms. We flock to buy tickets for